| pubmed-article:11870166 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11870166 | lifeskim:mentions | umls-concept:C1140680 | lld:lifeskim |
| pubmed-article:11870166 | lifeskim:mentions | umls-concept:C0012634 | lld:lifeskim |
| pubmed-article:11870166 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11870166 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:11870166 | lifeskim:mentions | umls-concept:C0677886 | lld:lifeskim |
| pubmed-article:11870166 | lifeskim:mentions | umls-concept:C0079083 | lld:lifeskim |
| pubmed-article:11870166 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:11870166 | lifeskim:mentions | umls-concept:C1442792 | lld:lifeskim |
| pubmed-article:11870166 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:11870166 | lifeskim:mentions | umls-concept:C0185125 | lld:lifeskim |
| pubmed-article:11870166 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:11870166 | lifeskim:mentions | umls-concept:C0205265 | lld:lifeskim |
| pubmed-article:11870166 | lifeskim:mentions | umls-concept:C1514923 | lld:lifeskim |
| pubmed-article:11870166 | lifeskim:mentions | umls-concept:C1555582 | lld:lifeskim |
| pubmed-article:11870166 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:11870166 | pubmed:dateCreated | 2002-2-28 | lld:pubmed |
| pubmed-article:11870166 | pubmed:abstractText | The majority of patients with epithelial ovarian cancer (EOC) who achieve a complete remission with front-line chemotherapy develop recurrent disease. Carboplatin and paclitaxel are used for patients with platinum-sensitive recurrent disease, although there is little information regarding the response and survival in unselected patients treated with this strategy. We sought to determine the outcomes for patients with EOC treated with carboplatin and paclitaxel at the time of first recurrence. In addition, we sought to define a new paradigm for disease transition in patients with EOC. | lld:pubmed |
| pubmed-article:11870166 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11870166 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11870166 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11870166 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11870166 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11870166 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11870166 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11870166 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11870166 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11870166 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11870166 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11870166 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11870166 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:11870166 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:11870166 | pubmed:author | pubmed-author:SabbatiniPaul... | lld:pubmed |
| pubmed-article:11870166 | pubmed:author | pubmed-author:VenkatramanEn... | lld:pubmed |
| pubmed-article:11870166 | pubmed:author | pubmed-author:AghajanianCar... | lld:pubmed |
| pubmed-article:11870166 | pubmed:author | pubmed-author:DizonDon SDS | lld:pubmed |
| pubmed-article:11870166 | pubmed:author | pubmed-author:HensleyMartee... | lld:pubmed |
| pubmed-article:11870166 | pubmed:author | pubmed-author:SpriggsDavid... | lld:pubmed |
| pubmed-article:11870166 | pubmed:author | pubmed-author:PoynorElizabe... | lld:pubmed |
| pubmed-article:11870166 | pubmed:author | pubmed-author:HummerAmandaA | lld:pubmed |
| pubmed-article:11870166 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11870166 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:11870166 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:11870166 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11870166 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11870166 | pubmed:pagination | 1238-47 | lld:pubmed |
| pubmed-article:11870166 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:11870166 | pubmed:meshHeading | pubmed-meshheading:11870166... | lld:pubmed |
| pubmed-article:11870166 | pubmed:meshHeading | pubmed-meshheading:11870166... | lld:pubmed |
| pubmed-article:11870166 | pubmed:meshHeading | pubmed-meshheading:11870166... | lld:pubmed |
| pubmed-article:11870166 | pubmed:meshHeading | pubmed-meshheading:11870166... | lld:pubmed |
| pubmed-article:11870166 | pubmed:meshHeading | pubmed-meshheading:11870166... | lld:pubmed |
| pubmed-article:11870166 | pubmed:meshHeading | pubmed-meshheading:11870166... | lld:pubmed |
| pubmed-article:11870166 | pubmed:meshHeading | pubmed-meshheading:11870166... | lld:pubmed |
| pubmed-article:11870166 | pubmed:meshHeading | pubmed-meshheading:11870166... | lld:pubmed |
| pubmed-article:11870166 | pubmed:meshHeading | pubmed-meshheading:11870166... | lld:pubmed |
| pubmed-article:11870166 | pubmed:meshHeading | pubmed-meshheading:11870166... | lld:pubmed |
| pubmed-article:11870166 | pubmed:meshHeading | pubmed-meshheading:11870166... | lld:pubmed |
| pubmed-article:11870166 | pubmed:meshHeading | pubmed-meshheading:11870166... | lld:pubmed |
| pubmed-article:11870166 | pubmed:meshHeading | pubmed-meshheading:11870166... | lld:pubmed |
| pubmed-article:11870166 | pubmed:meshHeading | pubmed-meshheading:11870166... | lld:pubmed |
| pubmed-article:11870166 | pubmed:meshHeading | pubmed-meshheading:11870166... | lld:pubmed |
| pubmed-article:11870166 | pubmed:meshHeading | pubmed-meshheading:11870166... | lld:pubmed |
| pubmed-article:11870166 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11870166 | pubmed:articleTitle | Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. | lld:pubmed |
| pubmed-article:11870166 | pubmed:affiliation | Department of Medicine, Division of Developmental Chemotherapy, and Department of Gynecologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY. | lld:pubmed |
| pubmed-article:11870166 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11870166 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11870166 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11870166 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11870166 | lld:pubmed |
